

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

Date: (Filing No. S- )

**HEALTH COVERAGE, INSURANCE AND FINANCIAL SERVICES**

Reproduced and distributed under the direction of the Secretary of the Senate.

**STATE OF MAINE  
SENATE  
130TH LEGISLATURE  
FIRST SPECIAL SESSION**

COMMITTEE AMENDMENT “ ” to S.P. 380, L.D. 1117, “An Act To Prevent Excessive Prices for Prescription Drugs”

Amend the bill by striking out the title and substituting the following:

**'Resolve, To Identify Generic or Off-patent Prescription Drugs with Excessive Price Increases in the State'**

Amend the bill by striking out everything after the title and inserting the following:

**'Sec. 1. Identification of generic or off-patent prescription drugs with excessive price increases. Resolved:** That the Maine Health Data Organization shall identify each generic or off-patent prescription drug that during 2020 and, to the extent information is available, during 2021 had an excessive price increase and identify the manufacturer of that drug. For the purposes of this resolve, a price increase of a generic or off-patent prescription drug is excessive when the price increase, adjusted for inflation using the Consumer Price Index, exceeds 20% of the wholesale acquisition cost per pricing unit during calendar year 2019 and the cost of the drug is at least \$10 per pricing unit as defined in the Maine Revised Statutes, Title 22, section 8731, subsection 5.

**Sec. 2. Additional information required. Resolved:** That, in addition to the identification under section 1 of the generic or off-patent prescription drugs having an excessive price increase and the manufacturers of those drugs, the Maine Health Data Organization shall determine the following for a prescription drug manufacturer of each generic or off-patent prescription drug identified as having an excessive price increase:

- 1. An accounting of all revenues generated in this State from the sale of a drug with an excessive price increase, comparing the sales in this State in 2019 before the excessive price increase to the sales in this State in 2020 and 2021, if information is available, during the period in which the excessive price increase applied;
- 2. An itemization of the components of the cost of producing the drug;

**COMMITTEE AMENDMENT**

